Firebrick Pharma (ASX:FRE) Dividends per Share : A$0.00 (TTM As of Dec. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Firebrick Pharma Dividends per Share?

Firebrick Pharma's dividends per share for the six months ended in Dec. 2024 was A$0.00. Its dividends per share for the trailing twelve months (TTM) ended in Dec. 2024 was A$0.00. Its Dividend Payout Ratio for the six months ended in Dec. 2024 was 0.00. As of today, Firebrick Pharma's Dividend Yield % is 0.00%.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

For more information regarding to dividend, please check our Dividend Page.

* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.

Firebrick Pharma Dividends per Share Historical Data

The historical data trend for Firebrick Pharma's Dividends per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Firebrick Pharma Dividends per Share Chart

Firebrick Pharma Annual Data

Trend

Jun21

Jun22

Jun23

Jun24

Dividends per Share

Firebrick Pharma Semi-Annual Data
	Jun21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Dividends per Share	Get a 7-Day Free Trial			-	-	-	-	-

Competitive Comparison of Firebrick Pharma's Dividends per Share

For the Drug Manufacturers - General subindustry, Firebrick Pharma's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Firebrick Pharma's Dividend Yield % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Firebrick Pharma's Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Firebrick Pharma's Dividend Yield % falls into.

Save Embed

;

Save Embed

;

Firebrick Pharma Dividends per Share Calculation

Dividends paid to per common share.

Firebrick Pharma (ASX:FRE) Dividends per Share Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

Firebrick Pharma's Dividend Payout Ratio for the quarter that ended in Dec. 2024 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Dec. 2024 )	/	EPS without NRI (Q: Dec. 2024 )
	=	0	/	-0.007
	=	N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

Firebrick Pharma Dividends per Share Related Terms

Thank you for viewing the detailed overview of Firebrick Pharma's Dividends per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Firebrick Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Firebrick Pharma Ltd (ASX:FRE) » Definitions » Dividends per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

440 Collins Street, Level 10, Melbourne, VIC, AUS, 3000

Website

https://www.firebrickpharma.com

Firebrick Pharma Ltd is an Australian pharmaceutical developer. It is engaged in the development and commercialization of povidone-iodine (PVP-I) products under the Nasodine brand. Its Nasodine Nasal Spray which is in the commercialization phase, is a broad-spectrum anti-viral spray, designed to be an effective treatment and prevention of respiratory viral infections such as the common cold. In parallel, the company is also engaged in the development of the follow-on Nasodine brand products.

Firebrick Pharma Headlines

No Headlines